Philips Launches ECG AI Marketplace to Enhance Early Cardiac Diagnosis
Philips (NYSE: PHG) has launched the ECG AI Marketplace, a centralized platform enabling cardiac care teams to access multiple AI-powered diagnostic tools from different vendors. Anumana becomes the first partner, integrating its FDA-cleared ECG-AI™ LEF algorithm for detecting low ejection fraction, an early indicator of heart failure.
The marketplace streamlines workflow integration and vendor management for U.S. hospitals and health systems using Philips' infrastructure. Anumana's algorithm, validated through studies involving over 150,000 patients and supported by nearly 100 peer-reviewed publications, will be available across Philips' ECG portfolio, including IntelliSpace ECG and Philips cardiographs.
Philips (NYSE: PHG) ha lanciato il ECG AI Marketplace, una piattaforma centralizzata che consente ai team di cardiologia di accedere a diversi strumenti diagnostici basati su intelligenza artificiale offerti da vari fornitori. Anumana è il primo partner, integrando il suo algoritmo ECG-AI™ LEF approvato dalla FDA per rilevare la frazione di eiezione bassa, un indicatore precoce di insufficienza cardiaca.
Il marketplace semplifica l'integrazione dei flussi di lavoro e la gestione dei fornitori per ospedali e sistemi sanitari statunitensi, sfruttando l'infrastruttura Philips. L'algoritmo di Anumana, validato attraverso studi che hanno coinvolto oltre 150.000 pazienti e supportato da quasi 100 pubblicazioni peer-reviewed, sarà disponibile in tutta la gamma di dispositivi ECG di Philips, inclusi IntelliSpace ECG e i cardiografi Philips.
Philips (NYSE: PHG) ha lanzado el ECG AI Marketplace, una plataforma centralizada que permite a los equipos de atención cardiaca acceder a múltiples herramientas diagnósticas impulsadas por IA de diferentes proveedores. Anumana se convierte en el primer socio, integrando su algoritmo ECG-AI™ LEF aprobado por la FDA para detectar la fracción de eyección baja, un indicador temprano de insuficiencia cardíaca.
El marketplace facilita la integración de flujos de trabajo y la gestión de proveedores para hospitales y sistemas de salud en EE. UU., utilizando la infraestructura de Philips. El algoritmo de Anumana, validado mediante estudios con más de 150,000 pacientes y respaldado por casi 100 publicaciones revisadas por pares, estará disponible en toda la cartera de ECG de Philips, incluyendo IntelliSpace ECG y los cardiógrafos Philips.
필립스 (NYSE: PHG)는 여러 공급업체의 AI 기반 진단 도구에 심장 진료팀이 접근할 수 있도록 하는 중앙 집중식 플랫폼인 ECG AI 마켓플레이스를 출시했습니다. Anumana는 FDA 승인 ECG-AI™ LEF 알고리즘을 통합한 첫 번째 파트너로, 이는 심부전의 초기 지표인 저박출률을 감지합니다.
이 마켓플레이스는 필립스 인프라를 활용하여 미국 병원 및 의료 시스템의 워크플로우 통합과 공급업체 관리를 간소화합니다. Anumana의 알고리즘은 15만 명 이상의 환자를 대상으로 한 연구를 통해 검증되었으며, 약 100건의 동료 검토 출판물로 뒷받침됩니다. 이 알고리즘은 IntelliSpace ECG 및 필립스 심전도기를 포함한 필립스 ECG 제품군 전반에 제공될 예정입니다.
Philips (NYSE: PHG) a lancé le ECG AI Marketplace, une plateforme centralisée permettant aux équipes de soins cardiaques d’accéder à plusieurs outils diagnostiques basés sur l’IA provenant de différents fournisseurs. Anumana devient le premier partenaire en intégrant son algorithme ECG-AI™ LEF approuvé par la FDA pour détecter la faible fraction d’éjection, un indicateur précoce d’insuffisance cardiaque.
Le marketplace facilite l’intégration des flux de travail et la gestion des fournisseurs pour les hôpitaux et systèmes de santé américains en utilisant l’infrastructure Philips. L’algorithme d’Anumana, validé par des études impliquant plus de 150 000 patients et soutenu par près de 100 publications évaluées par des pairs, sera disponible sur l’ensemble du portefeuille ECG de Philips, incluant IntelliSpace ECG et les cardiographes Philips.
Philips (NYSE: PHG) hat den ECG AI Marketplace gestartet, eine zentrale Plattform, die kardiologischen Teams den Zugriff auf mehrere KI-gestützte Diagnosewerkzeuge verschiedener Anbieter ermöglicht. Anumana ist der erste Partner und integriert seinen FDA-zugelassenen ECG-AI™ LEF Algorithmus zur Erkennung einer niedrigen Ejektionsfraktion, einem frühen Indikator für Herzinsuffizienz.
Der Marketplace vereinfacht die Workflow-Integration und das Lieferantenmanagement für US-Krankenhäuser und Gesundheitssysteme unter Nutzung der Philips-Infrastruktur. Anumanas Algorithmus, validiert durch Studien mit über 150.000 Patienten und gestützt auf nahezu 100 peer-reviewed Publikationen, wird im gesamten Philips-ECG-Portfolio verfügbar sein, einschließlich IntelliSpace ECG und Philips-Kardiographen.
- None.
- None.
Insights
Philips' new ECG AI Marketplace streamlines cardiac AI adoption, with Anumana's heart failure detection algorithm as first integration.
Philips' launch of their ECG AI Marketplace represents a strategic expansion of their cardiac diagnostic ecosystem through an open platform approach. This marketplace addresses a critical pain point in healthcare IT: the fragmentation of AI tools across multiple vendors that creates integration challenges and inefficiencies. By centralizing AI algorithm access, Philips is positioning itself as a critical infrastructure provider in the cardiac AI space.
The initial partnership with Anumana brings FDA-cleared technology for detecting Low Ejection Fraction (LEF), an early indicator of heart failure, to Philips' extensive ECG infrastructure. What makes this particularly valuable is that it enables earlier detection of heart failure through routine ECG readings - potentially identifying at-risk patients before symptoms become severe. Anumana's algorithm has undergone rigorous validation across 150,000+ patients with nearly 100 peer-reviewed publications supporting its efficacy.
From a market perspective, this marketplace model creates a network effect opportunity - as more algorithm vendors join, the platform becomes more valuable to healthcare providers, which attracts more vendors. By establishing this ecosystem, Philips is creating a strategic moat in cardiac diagnostics while addressing the growing complexity of managing multiple AI solutions in clinical settings.
The integration into existing Philips infrastructure (IntelliSpace ECG and cardiographs) means hospitals can leverage their current investments while adding new AI capabilities, reducing implementation barriers and potentially accelerating adoption rates.
July 17, 2025
Anumana's FDA-cleared LEF algorithm becomes first certified third-party solution available through Philips’ ECG ecosystem
CAMBRIDGE, Mass. — Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of the Philips ECG AI Marketplace, a platform that gives cardiac care teams access to multiple vendor offerings all in one central location to help clinicians manage and implement AI-powered diagnostic tools more easily. Anumana, an AI-driven health technology company committed to transforming the continuum of cardiac care, is the first organization to leverage Philips’ platform. Its FDA-cleared ECG-AI™ LEF (Low Ejection Fraction) algorithm will be available in the Philips ECG AI Marketplace.
As clinicians become more comfortable using AI-powered tools, healthcare organizations have adopted multiple vendors’ platforms and solutions. The Philips ECG AI Marketplace enables U.S. hospitals and health systems to integrate validated algorithms into their workflow and existing Philips infrastructure. The Marketplace also gives cardiac care teams direct access to a broad portfolio of AI tools at the point of care, helping reduce the time it takes for clinicians to review ECG results and fast-track diagnoses for patients. The platform’s ability to manage vendor connections for each AI solution also improves operational costs and efficiency by removing the need to devote hospital IT resources to overseeing the different interfaces for every tool.
“Through the Philips ECG AI Marketplace, we’re building a more flexible and connected approach to innovation in cardiac care,” said Stefano Folli, Business Leader, Ambulatory Monitoring and Diagnostics, Philips. “The Philips ECG AI Marketplace meets a growing need for easier access and management of AI-enabled tools to improve the healthcare experience for clinicians and patients. Our collaboration with Anumana is a strong example of how these tools can support both earlier detection of heart diseases and accelerate patient care.”
Anumana’s FDA breakthrough-designated LEF algorithm is now integrated across Philips’ ECG portfolio through the Philips ECG AI Marketplace, including IntelliSpace ECG and Philips cardiographs. The LEF algorithm analyzes a standard 12-lead resting ECG to identify reduced ejection fraction, an early indicator of heart failure. With Anumana’s algorithm now available through the Philips ECG AI Marketplace, healthcare providers can access AI-powered cardiac insights during routine ECG ordering and interpretation, supporting timely and informed care.
“We’re proud to be the flagship offering on the Philips ECG AI Marketplace,” said Simos Kedikoglou, MD, President and Chief Operating Officer at Anumana. “Working with Philips expands access to our ECG-AI technology through a trusted platform, starting with our cleared LEF algorithm and extending to our full suite of point-of-care algorithms as they receive FDA regulatory clearance. Anumana’s AI algorithms, including for LEF detection, have been extensively evaluated in studies involving more than 150,000 patients and are supported by nearly 100 peer-reviewed publications. By making early detection tools available across multiple platforms, this collaboration helps clinicians intervene sooner, reflecting a shared commitment to improving outcomes for patients at risk of heart failure.”
The collaboration with Anumana is part of the continuing expansion by Philips to open its ECG ecosystem to third-party solutions, to ease integration and support clinical decision-making. By making AI diagnostics more available to cardiac care teams, Philips aims to improve access to early cardiovascular disease detection and care.
For further information, please contact:
Philips
Allison Johnson
Director, Monitoring Communications
Tel: +1 617-631-7305
E-mail: allison.johnson@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.
Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,200 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Attachment
FAQ
What is Philips' new ECG AI Marketplace and how does it work?
What is the first AI algorithm available on Philips' ECG AI Marketplace?
How has Anumana's LEF algorithm been validated?
Which Philips systems will integrate with the ECG AI Marketplace?
How does the ECG AI Marketplace benefit hospitals and healthcare systems?
